Organon and Samsung Bioepis announced that Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab), is now available in the US. Hadlima® is available at a list price of $1,038, an 85% discount in comparison to the list price of Humira®. Samsung Bioepis announced a global settlement with AbbVie in April 2018, under which Samsung Bioepis was licensed to supply biosimilar adalimumab in the US from 30 June 2023, and in EU from 16 October 2018.
On 1 July 2023, the following biosimilar entities are licensed to launch: Alvotech, Celltrion, Boehringer Ingelheim, Coherus before Fresenius Kabi in July (on an unspecified date), Mylan/Viatris on 31 July 2023, Sandoz on 30 September 2023, Momenta and Pfizer on 20 November 2023.